← Back to Search

Dopamine Antagonist

Domperidone for Gastroparesis and Acid Reflux

N/A
Recruiting
Led By Jose Cocjin, MD
Research Sponsored by Children's Mercy Hospital Kansas City
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation that are refractory to standard therapy.
Male or female aged 12 - 21
Must not have
Gastrointestinal hemorrhage or obstruction
Presence of a prolactinoma (prolactin-releasing pituitary tumor)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial program will allow the use of domperidone in children with motility disorders and GERD who have failed standard treatments.

Who is the study for?
This trial is for children and young adults aged 12-21 with severe symptoms of GERD or gastroparesis that haven't improved with standard treatments. They must understand the risks, including heart issues and hormonal changes, and not be pregnant, breastfeeding, or have certain heart conditions or allergies to domperidone.
What is being tested?
Domperidone is being used compassionately for those who have not responded to typical therapies for motility disorders like gastroparesis and GERD-related symptoms. The trial aims to provide relief from nausea, vomiting, and other digestive problems.
What are the potential side effects?
Possible side effects include increased levels of a hormone called prolactin which can lead to breast changes; movement disorders; heart rhythm problems such as QT prolongation; and potential interactions with specific drugs and herbal supplements.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have severe GERD symptoms or stomach issues not relieved by standard treatments.
Select...
I am between 12 and 21 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had bleeding or blockage in my digestive tract.
Select...
I have a tumor in my pituitary gland that releases prolactin.
Select...
I have a slow heartbeat or heart rhythm issue, and my QTc interval is longer than normal.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in disease severity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Overall StudyExperimental Treatment1 Intervention
Receive domperidone 4 times a day, weight-dependent dose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Domperidone
2011
Completed Phase 4
~401020

Find a Location

Who is running the clinical trial?

Children's Mercy Hospital Kansas CityLead Sponsor
257 Previous Clinical Trials
940,476 Total Patients Enrolled
Jose Cocjin, MDPrincipal InvestigatorChildren's Mercy Hospital Kansas City

Media Library

Domperidone (Dopamine Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT04699591 — N/A
Gastroparesis Research Study Groups: Overall Study
Gastroparesis Clinical Trial 2023: Domperidone Highlights & Side Effects. Trial Name: NCT04699591 — N/A
Domperidone (Dopamine Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04699591 — N/A
~10 spots leftby Dec 2035